We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other diseases of the respiratory systemMalignant neoplasms of respiratory and intrathoracic organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Low-dose CT (LDCT) screening for lung cancer (LCS) has been shown to reduce lung cancer specific mortality in multiple randomised controlled trials. However, although LDCT screening has been demonstrated to reduce cancer-specific mortality, there remain outstanding questions regarding how screening can be implemented. In particular, indeterminate nodules are common, and can be challenging to distinguish from benign nodules on CT appearances alone. Furthermore, distinguishing cancers which are likely to become clinically significant from those that will remain indolent is challenging, but essential to prevent over-treatment and overdiagnosis. There is significant interest in using a multi-modal approach to LCS, incorporating biomarkers obtained from minimally-invasive samples alongside LDCT to improve ability to recognise clinically-significant lung cancers at an early stage.
The Targeted Lung Health Check (TLHC) programme is an NHS programme with the aim of using LDCT screening in appropriately high-risk individuals to improve early diagnosis and survival in lung cancer. The North Central London TLHC programme is due to start in mid-2022.
The purpose of the ALPINE study is to develop a platform to allow collection of minimally-invasive samples (potentially including but not limited to peripheral blood, buccal swabs, stool samples and exhaled breath condensate) from participants undergoing screening within the North Central London TLHC programme. The use of such biomarkers in the diagnosis of lung cancer is a rapidly developing field and novel techniques and technologies are continuously under development. The ALPINE study will generate a cohort with matched biosamples, CT scans and clinical data which will be uniquely well placed to serve to develop or validate biomarkers in lung cancer screening and risk prediction.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Exclusion criteria for the North Central London NHS Targeted Lung Health Checks are: • Participant does not have capacity to give consent (standard criteria for assessing capacity apply); • Full thoracic CT scan within the last 12 months or planned, for clinical reasons, in the next 3 months (Note, may still be included if CT essentially equates to a baseline scan and there are no other exclusion criteria); • Weight exceeds restrictions for scanner (> 200kg); • Participant unable to lie flat; or • Poor physical fitness such that treatment with curative intent would be contra-indicated; this may require a second opinion or advice from the local lung cancer MDT 2. Lacking capacity and unable to provide written consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University College London and funded by CANCER RESEARCH UK; UK Research and Innovation (UKRI); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56278
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
